Determining volatile organic compounds in human blood from a large sample population by using purge and trap gas chromatography/mass spectrometry.

Volatile organic compounds (VOCs) are a major public health concern, because of their ubiquitous nature and the possible health effects associated with exposure to them. An analytical method has been developed that enabled the determination of parts per trillion levels of 32 VOCs in 10 mL of blood. Special efforts toward reducing blank levels and improving measurement sensitivity have resulted in an analytical method that shows excellent reproducibility and recovery even at these ultratrace levels. Results on normal human blood indicate that quantifiable levels of eleven VOCs can be found in virtually all whole blood samples. In a fraction of the samples, six other VOCs can also be determined at levels above detection limits. This method shows promise as a technique for estimating the normal baseline level of VOCs in human blood and may have future applications in cases of exposure.     

Application of gas chromatography/mass spectrometry (GC/MS) and pyrolysis-gas chromatography/mass spectrometry (Py-GC/MS) in failure analysis in the automotive industry

This paper describes the application examples of gas chromatography/mass spectrometry (GC/MS) and pyrolysis–gas chromatography/mass spectrometry (Py-GC/MS) in failure analysis for the identification of chemical materials like mineral oil from a malfunctioning motorbike and a complaint car tire rubber. Furthermore, failure case demanding identification of chemical composition of solid plastic particles from a failed mechanical engineering component is demonstrated. The obtained analytical results were then used for troubleshooting and remedial action of the technological processes.     

Development of a multibed sorption trap, comprehensive two-dimensional gas chromatography, and time-of-flight mass spectrometry system for the analysis of volatile organic compounds in human breath

A method for the determination of volatile organic compounds (VOCs) at sub-trace levels in breath samples based on a multibed sorption trap for the collection and concentration of VOCs, a comprehensive multidimensional gas chromatograph (GCxGC) for the separation of complex mixtures, and a time-of-flight mass spectrometer detector is designed and developed. The good performance of the trap tube device developed for the concentration together with the high sensitivity and separation power of the GCxGC results in a powerful system. In the analysis of samples, more than 100 different compounds are detected of which between 65 and 85 are clearly identified. A total of approximately 250 different compounds are observed in all the samples evaluated of which 142 are identified. A preliminary study to evaluate breath biomarkers for active smoking is performed. The levels of previously described biomarkers are found to be strongly time-dependent with amounts found approximately 1 h after smoking returning to the levels found in nonsmoking volunteers. However, 2,5-dimethylfuran, 2-methylfuran, and furan are found to be effective biomarkers given that they were only found in samples taken from smokers and could still be detected more than 2 h after smoking.     

A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro(2-methylpyridine)platinum(II) in human plasma ultrafiltrate

The clinical use of platinum drugs as anticancer agents has encountered problems when relating pharmacokinetic profiles with efficacy and toxicity is attempted. This has been mainly due to the lack of specific and sensitive analytical methodology to examine concentrations of the unbound drug in plasma. The presence of a carbocyclic ring on the new drug, cis-amminedichloro(2-methylpyridine)platinum(II) (ZD0473) suggested that it would be possible to develop the first stable isotope dilution LC/MS assay for a platinum drug in human plasma ultrafiltrate samples. The dichloro form of the drug exists in equilibrium with at least two aquated forms in plasma. The molecular form of the drug, therefore, depends on the length of time that the plasma sample is maintained at room temperature before freezing. Therefore, we have developed a method that quantitatively converts the aquated species back to the dichloro form of the parent drug so that a single molecular species can be analyzed. Selected reaction monitoring was performed on the transition of m/z 393 [M + NH4]+ to m/z 304 [M + NH4 -NH3 - 2 x HCl]- for ZD0473, and m/z 400 [M + NH4]+ to m/z 310 [M + NH4 - NH3 - HCl - 2HCl]+ for [2H7]ZD0473. The standard curves were fitted to a quadratic regression over the range from 10 to 5000 ng/mL in human plasma ultrafiltrate. The lower limit of quantitation for ZD0473 was 10 ng/mL for 100 microL of plasma ultrafiltrate. This simple, rapid, reliable, and sensitive method of quantitation had excellent accuracy and precision. The method provided adequate sensitivity for the analysis of plasma ultrafiltrate samples from a phase II study in which ZD0473 was administered to patients as an intravenous infusion at a dose of 150 mg/m2.     

Determination of lysergic acid diethylamide (LSD), iso-LSD, and N-demethyl-LSD in body fluids by gas chromatography/tandem mass spectrometry.

Procedures for detection and quantitation of lysergic acid diethylamide (LSD), iso-LSD, and N-demethyl-LSD by capillary chromatography/tandem mass spectrometry (GC/MS/MS) are presented. Several methods for derivatization, sample introduction, and ionization, in combination with mass spectrometry/mass spectrometry (MS/MS), have been evaluated for overall ionization efficiency and product-ion sensitivity and specificity. Fragmentation pathways derived from low-energy collision-induced dissociation (CID) spectra of protonated LSD, and the protonated trimethylsllyl derivatives of LSD (LSD-TMS) and deuterium-labeled analogs of LSD, have been proposed. Principal dissociations primarily involve the amide and piperidine-ring moieties in which losses of CH3 radical, CH3NH2, CH3NCH2, diethylamine, diethylformamide, and N,N-diethylpropenamide from MH+ are observed. Positive-ion ammonia chemical ionization and subsequent MS/MS analysis of the protonated molecules (MH+) of the trimethylsilyl (TMS) derivatives of LSD, iso-LSD, and N-demethyl-LSD provide a high degree of specificity for identification of these compounds in urine or blood at low-pg/mL concentrations. Negative-ion chemical ionization and GC/MS/MS analysis of the molecular anion (M-) of the trifluoroacetyl (TFA) derivative is well suited for trace-level identification of N-demethyl-LSD, a metabolite of LSD.     

Determination of chromium in urine by stable isotope dilution gas chromatography/mass spectrometry using lithium bis(trifluoroethyl)dithiocarbamate as a chelating agent

An isotope dilution gas chromatography/mass spectrometry method using lithium bis(trifluoroethyl)dithiocarbamate as a chelating agent is described for the determination of chromium in urine. A wet digestion procedure with HNO3-H2O2 is used for oxidizing the organic matter associated with urine samples. The isotope ratios are measured by selected ion monitoring in a general-purpose mass spectrometer using a 10-m fused silica capillary column. Memory effect, in sequential analyses of samples with different isotope ratios, was evaluated by preparing a series of synthetic mixtures and was found to be negligible. The accuracy of the method was verified by quantitation of chromium in the NIST freeze-dried urine reference material, SRM-2670, with a recommended chromium concentration of 13 micrograms/L in the normal level and certified chromium concentration of 85 +/- 6 micrograms/L in the elevated level.     

Analysis of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in urine by extraction on a molecularly imprinted polymer column and liquid chromatography/atmospheric pressure ionization tandem mass spectrometry

The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) is present in the urine of tobacco users and, at lower concentrations, in the urine of nonsmokers exposed to secondhand smoke. NNAL is a valuable biomarker of human exposure to the carcinogenic nitrosamines in tobacco and tobacco smoke, but its presence at low concentrations in urine requires sensitive and often complex analytic procedures. In this report, we describe the development of an efficient method for the analysis of NNAL in human urine using liquid chromatography/atmospheric pressure ionization tandem mass spectrometry (LC/MS/MS) combined with a novel sample cleanup based on a molecularly imprinted polymer (MIP) column developed specifically for this assay. Our results suggest that this combination of MIP column extraction and LC/MS/MS can provide a sensitive and relatively simple analytical method suitable for application to epidemiologic investigations of health risks associated with the exposure to tobacco smoke or SHS in both smokers and nonsmokers.     

Quantification of the heterocyclic aromatic amine DNA adduct N-(deoxyguanosin-8-yl)-2-amino-3-methylimidazo[4,5-f]quinoline in livers of rats using capillary liquid chromatography/microelectrospray mass spectrometry: a dose-response study

Capillary liquid chromatography/microelectrospray-mass spectrometry (capillary LC/muESI-MS) was used to quantify DNA adducts of the heterocyclic aromatic amine 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in livers of male Fischer-344 rats. Animals received a single oral dose of either 0.05, 0.50, 1.0, or 10 mg/kg IQ and were sacrificed 24 h following treatment. The major lesion identified at all doses was N-(deoxyguanosine-8-yl)-2-amino-3-methylimidazo[4,5-f]quinoline (dG-C8-IQ). The capillary LC/muESI-MS method provided the means for quantifying 17.5 fmol of dG-C8-IQ (2.0 adducts in 10(8) nucleosides) (S/N 10) in 300 microg of liver DNA with an intra- and interday precision of 3.5 and 6.6% (RSD), respectively. dG-C8-IQ was quantified with a mean intra- and interday accuracy of 105 +/- 26 and 106 +/- 28 (SD) based on back-calculated adduct masses from five standard curves analyzed over a four-week period. This is the first report on development of a capillary LC/muESI-MS method to quantify dG-C8-IQ adducts in liver DNA of rats following dosing with IQ at different levels. Furthermore, the ability to accurately and precisely quantify dG-C8-IQ at a level of 2.0 adducts in 10(8) nucleosides in vivo makes this method well suited for use in future studies relating carcinogen exposure to risk in humans.